menu
    • menu
    [{"orgOrder":0,"company":"ATLAS PHARMS LLC","sponsor":"TME Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Large Molecule","year":"2021","type":"Financing","leadProduct":"Emapticap pegol","moa":"||CCL2","graph1":"Oncology","graph2":"Phase II","graph3":"ATLAS PHARMS LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ATLAS PHARMS LLC \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"ATLAS PHARMS LLC \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"ATLAS PHARMS LLC","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"ATLAS PHARMS LLC","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"ATLAS PHARMS LLC \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"ATLAS PHARMS LLC \/ ATLAS PHARMS LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Atlas Biologicals

    Menu

    Atlas Biologicals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Recipient : Biophytis

                            Deal Size : $17.1 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities

                            Details : The financing aims to fund the Biophytis to advance the clinical development of BIO101 (20-hydroxyecdysone) first oral MAS receptor activator, which is being evaluated for treating obesity.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 19, 2024

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Recipient : Biophytis

                            Deal Size : $17.1 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emapticap pegol,Irinotecan Hydrochloride,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : TME Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under Financing Agr...

                            Details : As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            January 06, 2021

                            Lead Product(s) : Emapticap pegol,Irinotecan Hydrochloride,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : TME Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth